Fig. 1.

Candesartan inhibits the growth of prostate cancer xenograft in vivo at clinically relevant doses. (A) Representative pictures of PC3 cell prostate tumor xenografts showing reduced tumor size by treatment with clinically relevant doses of candesartan. (B) Graph showing the effect of clinical doses of candesartan on PC3 cell tumor xenograft volume as measured on days 12, 18, and 24 (6, 12, and 18 days post-treatment). (C) Bar graph showing the effect of clinical doses of candesartan on PC3 cell tumor xenograft weight on day 24, after 18-day treatment with candesartan. (D) Bar graph showing quantified data on the number of blood vessels surrounding the PC3 cell tumor xenografts in the presence and absence of clinical doses of candesartan. Data are presented as the mean ± S.D.